(Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors

You may be able to join if

• Histologically confirmed locally advanced, metastatic, and/or unresectable GIST (Molecular pathology report must be available for Part 2; if molecular pathology report is unavailable or inadequate, an archival or fresh tumor tissue sample will be required to evaluate mutational status prior to randomization.)
• Documented disease progression on or intolerance to imatinib. Imatinib intolerance is defined as discontinuation of imatinib due to (an) adverse event(s) related to treatment with imatinib that was not manageable with dose modifications.
• Subjects must have received the following treatment: − Part 1a: Treatment with ≥1 prior lines of therapy for GIST − Part 1b: Treatment with ≥2 prior TKI for GISTs. (Note: Each different TKI is counted once regardless of how often it was used. If 2 different TKIs were used in combination, both TKIs are counted.) − Part 2: Prior treatment with imatinib only
• Have at least 1 measurable lesion according to mRECIST v1.1 (non-nodal lesions must be ≥1.0 cm in the long axis or ≥double the slice thickness in the long axis)
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2
• other protocol defined inclusion criteria apply